Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Novel therapies are changing treatment paradigms in metastatic prostate cancer, Journal of Hematology & Oncology
Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
The treatment landscape of metastatic prostate cancer - ScienceDirect
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer
Rucaparib or physician's choice in metastatic prostate cancer - UROONCO Prostate Cancer
Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer - The ASCO Post
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
format(webp))
